IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+11.71%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$302M
AUM Growth
+$302M
(-1.5%)
Cap. Flow
-$35.1M
Cap. Flow
% of AUM
-11.6%
Top 10 Holdings %
Top 10 Hldgs %
44.95%
Holding
160
New
20
Increased
14
Reduced
32
Closed
33
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$10.5M |
| 2 |
Apogee Therapeutics
APGE
|
$10.1M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$8.15M |
| 4 |
Insmed
INSM
|
$7.95M |
| 5 |
Cogent Biosciences
COGT
|
$7.44M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$11.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$10.1M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$7.86M |
| 5 |
Scholar Rock
SRRK
|
$6.91M |
Sector Composition
| 1 | Healthcare | 99.76% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Edgewise Therapeutics
EWTX
$1.54B
| – | – |
-280,000
| Closed | -$6.16M |
|
152
Monte Rosa Therapeutics
GLUE
$309M
| – | – |
-136,575
| Closed | -$634K |
|
153
Harrow
HROW
$1.38B
| – | – |
0
| – | – |
|
154
Immunovant
IMVT
$2.91B
| – | – |
0
| – | – |
|
155
Incyte
INCY
$17B
| – | – |
0
| – | – |
|
156
Disc Medicine
IRON
$2.14B
| – | – |
0
| – | – |
|
|
ITOS
157
DELISTED
iTeos Therapeutics
ITOS
| – | – |
-78,585
| Closed | -$469K |
|
158
Keros Therapeutics
KROS
$640M
| – | – |
-274,009
| Closed | -$2.79M |
|
159
Kymera Therapeutics
KYMR
$3.1B
| – | – |
0
| – | – |
|
160
Eli Lilly
LLY
$661B
| – | – |
0
| – | – |
|